News

SPERA PHARMA, Bushu Pharmaceuticals Group’s new company, exhibited its services for the first time at Interphex 2017

At Interphex 2017, held from June 28 at the Tokyo Big Sight, SPERA PHARMA, a newly launched member of the Bushu Pharmaceuticals Group, exhibited its services for the first time. Despite the short notice, more than 100 visitors came to our exhibit during this 3-day event.

SPERA PHARMA is a Contract Development and Manufacturing Organization (CDMO), created as a spin-out organization by CMC research experts at Takeda Pharmaceutical Company. A team of specialists, building on an outstanding research record, have established this new company as an affiliate of the Bushu Pharmaceuticals Group. With the launch of operations on July 1 close at hand, SPERA PHARMA displayed, inside the Bushu Pharmaceuticals booth, its corporate concept and details of the major services it will offer as new business operations. CMC researchers at SPERA PHARMA enthusiastically conversed with visitors to the display booth, sharing information on the new company’s services and cutting-edge technologies.

Many visitors were very interested in the topics of discussion with researchers—SPERA’s new CMC technologies, which have been highly rated globally, and the increasingly high technological hurdles in drug R&D, in particular those related to the highly advanced and internationally renowned asymmetric synthetic technologies.

As one SPERA PHARMA researcher who took part in the event commented, “I was able to have much more specialized and interesting discussions than I had anticipated. This experience inspired me to share my experiences at Takeda, and to make a broader contribution to the pharmaceutical industry by polishing them up even further.” Another researcher said, “It was a humbling experience to learn, prior to the start of our new business, how passionate people engaged in pharmaceutical R&D are about creating new drugs, and how high their expectations are for CMC technologies.”

SPERA PHARMA wishes to take this opportunity to thank, once again, everyone who came to the exhibition. At the same time, we promise to do our very best to address your comments and meet your expectations, providing as much assistance to you as possible.